Since hepatocyte apoptosis has been identified as an additional progression factor for MASLD [78], OPG could be involved in the pathogenesis due to its ability to block TRAIL-mediated effects. This evidence concerns the gene TNFRSF11B and metabolic dysfunction-associated steatotic liver disease.